10 July 2026 : Clinical Research
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Satoru Takahashi ABCDE 1, Mihoko Yamade ABCDF 1*, Takahisa Furuta A 2, Tomohiro Higuchi AB 3, Mikihiro Shimizu CD 4, Keisuke Inagaki B 1, Kiichi Sugiura B 1, Tomoharu Matsuura B 5, Natsuki Ishida
B 1, Takanori Yamada B 6, Moriya Iwaizumi F 5, Yasushi Hamaya B 1, Ken Sugimoto F 1, Satoshi Osawa DF 6,7
DOI: 10.12659/MSM.953332
Med Sci Monit 2026; 32:e953332
Table 2 Adverse events of the subjects enrolled in this study.
| Laboratory test | Control | VPZ (Day8) | ΔVPZ–Control |
|---|---|---|---|
| WBC, ×10/μL | 5.60 ± 1.26 | 6.13 ± 1.61 | 0.53 ± 1.43 |
| RBC, ×10/μL | 4.86 ± 0.38 | 4.93 ± 0.43 | 0.08 ± 0.23 |
| Hb, g/dL | 14.1 ± 1.1 | 14.3 ± 1.3 | 0.2 ± 0.9 |
| Plt, ×10/μL | 27.0 ± 5.9 | 27.4 ± 6.5 | 0.4 ± 6.5 |
| AST, U/L | 20.7 ± 5.8 | 21.5 ± 7.6 | 0.74 ± 9.8 |
| ALT, U/L | 18.1 ± 9.6 | 21.3 ± 10.9 | 3.2 ± 8.8 |
| LD, U/L | 179 ± 89 | 165 ± 33 | −14 ± 87 |
| ALP, U/L | 70.4 ± 17.9 | 73.7 ± 19.9 | 3.2 ± 10.0 |
| T. Bil, mg/dL | 0.77 ± 0.38 | 0.68 ± 0.38 | −0.09 ± 0.20 |
| BUN, mg/dL | 11.7 ± 2.9 | 12.6 ± 2.8 | 0.8 ± 2.6 |
| Cre, mg/dL | 0.71 ± 0.11 | 0.73 ± 0.09 | 0.02 ± 0.07 |
| Anaphylaxis | 0 | 0 | None |
| Gastrointestinal symptoms | 0 | 0 | None |
| Skin symptoms | 0 | 0 | None |
| Others | 0 | 0 | None |
| Data are expressed as mean ± SD. VPZ, vonoprazan; AE, adverse events; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; PLT, platelets; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LD, lactate dehydrogenase; ALP, alkaline phosphatase; T.Bil, total bilirubin; BUN, Blood urea nitrogen; Cre, creatinine. | |||